UCB
UCB | BR
Overview
Corporate Details
- ISIN(s):
- BE0002730118 (+5 more)
- LEI:
- 2138008J191VLSGY5A09
- Country:
- Belgium
- Address:
- ALLÉE DE LA RECHERCHE 60, 1070 ANDERLECHT
- Website:
- https://www.ucb.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
UCB is a global biopharmaceutical company that operates under the principle "Inspired by Patients. Driven by Science." The company focuses on the discovery, development, and commercialization of therapeutic solutions for people living with severe diseases. Its primary areas of scientific and clinical concentration are neurology and immunology. UCB aims to create value for patients by delivering innovative medicines and support services, such as its UCBCares® program, which assists patients and healthcare professionals throughout the treatment journey. Additionally, the company invests in external innovation through its corporate venture arm, UCB Ventures, which supports pioneering companies and technologies with the potential to treat severe diseases.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for UCB.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-12 20:00 |
Major Shareholding Notification
EN PR.pdf
|
English | 307.0 KB | |
| 2025-08-12 20:00 |
Major Shareholding Notification
FR PR.pdf
|
French | 294.4 KB | |
| 2025-08-12 20:00 |
Major Shareholding Notification
NL PR.pdf
|
Dutch | 289.3 KB | |
| 2025-07-31 07:00 |
Interim Report
UCB PR HY 2025 ENG.pdf
|
English | 615.4 KB | |
| 2025-07-31 07:00 |
Earnings Release
UCB PR HY 2025 FR.pdf
|
French | 590.2 KB | |
| 2025-07-31 07:00 |
Interim Report
UCB PR HY 2025 NL.pdf
|
Dutch | 983.3 KB | |
| 2025-07-31 07:00 |
Interim Report
UCB_Half-Year_2025_Report-EN-FINAL.pdf
|
English | 1.5 MB | |
| 2025-07-31 07:00 |
Interim Report
UCB_Half-Year_2025_Report-FR-FINAL.pdf
|
French | 1.5 MB | |
| 2025-07-31 07:00 |
Interim Report
UCB_Half-Year_2025_Report-NL-FINAL.pdf
|
Dutch | 1.5 MB | |
| 2025-07-10 20:00 |
Major Shareholding Notification
EN FMR 10.07.2025.pdf
|
English | 348.5 KB | |
| 2025-07-10 20:00 |
Major Shareholding Notification
FR FMR 10.07.2025.pdf
|
French | 304.0 KB | |
| 2025-07-10 20:00 |
Major Shareholding Notification
NL FMR 10.07.2025.pdf
|
Dutch | 304.0 KB | |
| 2025-07-08 20:00 |
Major Shareholding Notification
EN Transparency BR.pdf
|
English | 292.5 KB | |
| 2025-07-08 20:00 |
Major Shareholding Notification
FR Transparency BR.pdf
|
French | 294.4 KB | |
| 2025-07-08 20:00 |
Major Shareholding Notification
NL Transparency BR.pdf
|
Dutch | 299.5 KB |
Automate Your Workflow. Get a real-time feed of all UCB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for UCB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-28 | Caeymaex Emmanuel | Executive member | Sell | 2,597 | 389,420.15 EUR |
| 2025-04-22 | Peacock Jonathan | Board | Buy | 674 | 93,247.90 EUR |
| 2025-04-01 | Lund- Jürgensen Kirsten | Executive member | Buy | 2,143 | N/A |
| 2025-03-04 | Caeymaex Emmanuel | Executive member | Sell | 7,000 | 1,362,568.51 EUR |
| 2025-03-04 | Caeymaex Emmanuel | Executive member | Buy | 7,000 | 532,630.00 EUR |
| 2025-03-03 | Caeymaex Emmanuel | Executive member | Sell | 4,100 | 769,226.28 EUR |
| 2025-03-03 | Caeymaex Emmanuel | Executive member | Sell | 2,822 | 522,643.25 EUR |
| 2025-03-03 | Caeymaex Emmanuel | Executive member | Buy | 4,100 | 271,338.00 EUR |
| 2025-03-03 | Caeymaex Emmanuel | Executive member | Buy | 2,822 | 198,273.72 EUR |
| 2025-02-28 | Caeymaex Emmanuel | Executive member | Sell | 7,000 | 1,260,465.07 EUR |
